Nycomed's Instanyl (fentanyl) single-dose nasal spray receives European approval
(Thomson Reuters ONE) -
Nycomed /
Nycomed's Instanyl (fentanyl) single-dose nasal spray receives European approval
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* European Commission grants marketing authorisation for Nycomed's Instanyl
single-dose nasal spray for treatment of breakthrough pain (BTP) in cancer
patients
* Further extends the successful range of Instanyl nasal applications
* Provides patient-friendly, cost-effective treatment and greater flexibility
Nycomed today announced that the European Commission has granted marketing
authorisation for its Instanyl single-dose nasal spray. The single-dose nasal
spray marks another innovation by Nycomed in the management of breakthrough pain
in cancer patients and will be available in European countries from September
2011.
Instanyl fentanyl nasal spray has been developed by Nycomed. It was the first
fast acting nasal opioid approved for the management of breakthrough pain in
cancer patients, and was first approved in Europe in a multi-dose nasal spray in
2009.
The launch of the single-dose nasal spray will provide greater flexibility to
the patient and help to manage dose titration and dose modification, as well as
enabling easier tracking of patient's use of rescue medication.
The single-dose nasal spray will be available in all Instanyl dose strengths,
50 µg, 100 µg, and 200 µg.
Stein Kaasa, Professor at the Norwegian University of Science and Technology,
Trondheim (NTNU), said: "Instanyl represents a clear benefit for a large number
of cancer patients who suffer from breakthrough pain. The launch of the single-
dose nasal spray will ease the management of dose titration and modification,
which together with the nasal spray's safety and convenience should contribute
to further improving the management of breakthrough pain."
Guido Oelkers, Executive Vice President at Nycomed, added: "Development of the
Instanyl single-dose nasal spray further demonstrates Nycomed's commitment to
innovation in areas of clear medical need. Over half a million cancer patients
are suffering from breakthrough pain in Europe. The Instanyl single-dose nasal
spray will add flexibility to the managing of their pain."
About Breakthrough Pain (BTP)
Breakthrough pain is a transitory exacerbation of pain that occurs on a
background of otherwise controlled persistent pain. Up to 95% of patients with
cancer pain experience breakthrough pain, of which two-thirds experience
inadequate pain control. Untreated breakthrough pain has a profound impact on
patients' quality of life.
About Nycomed
Nycomed is a privately owned global pharmaceutical company with a diversified
portfolio focused on branded medicines in gastroenterology, respiratory and
inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC
products completes the portfolio.
Its R&D is structured around collaborations. In-licensing and expanding in
emerging markets are cornerstones of the company's growth strategy.
Nycomed employs 12,500 associates worldwide, and its products are sold in more
than 100 countries. It has strong platforms in Europe and in fast-growing
markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US
and Japan its products are available through best in class partners.
Headquartered in Zurich, Switzerland, the company generated total sales of
?3.2 billion in 2010 and an adjusted EBITDA of ?851 million.
For more information visitwww.nycomed.com
For further information
Media:
General phone: +41 44 555 15 10
Tobias Cottmann, phone: +41 44 555 15 01
Investors:
Christian B. Seidelin, phone: +41 44 555 11 04
This press release has been issued by Nycomed International Management GmbH,
Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon, Zurich, Switzerland.
--- End of Message ---
Nycomed
Thurgauerstrasse 130 Glattpark-Opfikon Switzerland
Press Release Instanyl Singl_DE:
http://hugin.info/144179/R/1528078/463790.pdf
Press Release Instanyl Singl_EN:
http://hugin.info/144179/R/1528078/463789.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Nycomed via Thomson Reuters ONE
[HUG#1528078]
Unternehmensinformation / Kurzprofil:
Datum: 04.07.2011 - 09:59 Uhr
Sprache: Deutsch
News-ID 56090
Anzahl Zeichen: 5245
contact information:
Town:
Glattpark-Opfikon
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 210 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nycomed's Instanyl (fentanyl) single-dose nasal spray receives European approval"
steht unter der journalistisch-redaktionellen Verantwortung von
Nycomed (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
